nodes	percent_of_prediction	percent_of_DWPC	metapath
Pregabalin—Sepsis—Methotrexate—lymphatic system cancer	0.0006	0.0006	CcSEcCtD
Pregabalin—Agitation—Carmustine—lymphatic system cancer	0.0006	0.0006	CcSEcCtD
Pregabalin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000597	0.000597	CcSEcCtD
Pregabalin—Asthenia—Fludarabine—lymphatic system cancer	0.000597	0.000597	CcSEcCtD
Pregabalin—Rash—Teniposide—lymphatic system cancer	0.000597	0.000597	CcSEcCtD
Pregabalin—Dermatitis—Teniposide—lymphatic system cancer	0.000597	0.000597	CcSEcCtD
Pregabalin—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000594	0.000594	CcSEcCtD
Pregabalin—Headache—Teniposide—lymphatic system cancer	0.000593	0.000593	CcSEcCtD
Pregabalin—Pruritus—Fludarabine—lymphatic system cancer	0.000589	0.000589	CcSEcCtD
Pregabalin—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000588	0.000588	CcSEcCtD
Pregabalin—Back pain—Mitoxantrone—lymphatic system cancer	0.000587	0.000587	CcSEcCtD
Pregabalin—Leukopenia—Carmustine—lymphatic system cancer	0.000584	0.000584	CcSEcCtD
Pregabalin—Anorexia—Bleomycin—lymphatic system cancer	0.000582	0.000582	CcSEcCtD
Pregabalin—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.00058	0.00058	CcSEcCtD
Pregabalin—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000577	0.000577	CcSEcCtD
Pregabalin—Anaemia—Vincristine—lymphatic system cancer	0.000576	0.000576	CcSEcCtD
Pregabalin—Agitation—Vincristine—lymphatic system cancer	0.000573	0.000573	CcSEcCtD
Pregabalin—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000572	0.000572	CcSEcCtD
Pregabalin—Polyuria—Methotrexate—lymphatic system cancer	0.000572	0.000572	CcSEcCtD
Pregabalin—Hypotension—Bleomycin—lymphatic system cancer	0.00057	0.00057	CcSEcCtD
Pregabalin—Diarrhoea—Fludarabine—lymphatic system cancer	0.000569	0.000569	CcSEcCtD
Pregabalin—Convulsion—Carmustine—lymphatic system cancer	0.000565	0.000565	CcSEcCtD
Pregabalin—Hypertension—Carmustine—lymphatic system cancer	0.000563	0.000563	CcSEcCtD
Pregabalin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000563	0.000563	CcSEcCtD
Pregabalin—Nausea—Teniposide—lymphatic system cancer	0.000562	0.000562	CcSEcCtD
Pregabalin—Anaemia—Mitoxantrone—lymphatic system cancer	0.000561	0.000561	CcSEcCtD
Pregabalin—Vertigo—Vincristine—lymphatic system cancer	0.00056	0.00056	CcSEcCtD
Pregabalin—Leukopenia—Vincristine—lymphatic system cancer	0.000558	0.000558	CcSEcCtD
Pregabalin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000556	0.000556	CcSEcCtD
Pregabalin—Chest pain—Carmustine—lymphatic system cancer	0.000556	0.000556	CcSEcCtD
Pregabalin—Myalgia—Carmustine—lymphatic system cancer	0.000556	0.000556	CcSEcCtD
Pregabalin—Anxiety—Carmustine—lymphatic system cancer	0.000554	0.000554	CcSEcCtD
Pregabalin—Paraesthesia—Bleomycin—lymphatic system cancer	0.000548	0.000548	CcSEcCtD
Pregabalin—Malaise—Mitoxantrone—lymphatic system cancer	0.000547	0.000547	CcSEcCtD
Pregabalin—Dyspnoea—Bleomycin—lymphatic system cancer	0.000544	0.000544	CcSEcCtD
Pregabalin—Renal failure acute—Methotrexate—lymphatic system cancer	0.000544	0.000544	CcSEcCtD
Pregabalin—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000543	0.000543	CcSEcCtD
Pregabalin—Convulsion—Vincristine—lymphatic system cancer	0.00054	0.00054	CcSEcCtD
Pregabalin—Hypertension—Vincristine—lymphatic system cancer	0.000538	0.000538	CcSEcCtD
Pregabalin—Confusional state—Carmustine—lymphatic system cancer	0.000537	0.000537	CcSEcCtD
Pregabalin—Oedema—Carmustine—lymphatic system cancer	0.000533	0.000533	CcSEcCtD
Pregabalin—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000532	0.000532	CcSEcCtD
Pregabalin—Decreased appetite—Bleomycin—lymphatic system cancer	0.00053	0.00053	CcSEcCtD
Pregabalin—Myalgia—Vincristine—lymphatic system cancer	0.00053	0.00053	CcSEcCtD
Pregabalin—Visual disturbance—Methotrexate—lymphatic system cancer	0.00053	0.00053	CcSEcCtD
Pregabalin—Cough—Mitoxantrone—lymphatic system cancer	0.000529	0.000529	CcSEcCtD
Pregabalin—Infection—Carmustine—lymphatic system cancer	0.000529	0.000529	CcSEcCtD
Pregabalin—Vomiting—Fludarabine—lymphatic system cancer	0.000529	0.000529	CcSEcCtD
Pregabalin—Convulsion—Mitoxantrone—lymphatic system cancer	0.000526	0.000526	CcSEcCtD
Pregabalin—Rash—Fludarabine—lymphatic system cancer	0.000525	0.000525	CcSEcCtD
Pregabalin—Dermatitis—Fludarabine—lymphatic system cancer	0.000524	0.000524	CcSEcCtD
Pregabalin—Hypertension—Mitoxantrone—lymphatic system cancer	0.000524	0.000524	CcSEcCtD
Pregabalin—Pain—Bleomycin—lymphatic system cancer	0.000522	0.000522	CcSEcCtD
Pregabalin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000522	0.000522	CcSEcCtD
Pregabalin—Headache—Fludarabine—lymphatic system cancer	0.000521	0.000521	CcSEcCtD
Pregabalin—Tachycardia—Carmustine—lymphatic system cancer	0.00052	0.00052	CcSEcCtD
Pregabalin—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000519	0.000519	CcSEcCtD
Pregabalin—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000517	0.000517	CcSEcCtD
Pregabalin—Chest pain—Mitoxantrone—lymphatic system cancer	0.000517	0.000517	CcSEcCtD
Pregabalin—Myalgia—Mitoxantrone—lymphatic system cancer	0.000517	0.000517	CcSEcCtD
Pregabalin—Anxiety—Mitoxantrone—lymphatic system cancer	0.000515	0.000515	CcSEcCtD
Pregabalin—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000512	0.000512	CcSEcCtD
Pregabalin—Lethargy—Methotrexate—lymphatic system cancer	0.000512	0.000512	CcSEcCtD
Pregabalin—Discomfort—Mitoxantrone—lymphatic system cancer	0.00051	0.00051	CcSEcCtD
Pregabalin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000508	0.000508	CcSEcCtD
Pregabalin—Oedema—Vincristine—lymphatic system cancer	0.000508	0.000508	CcSEcCtD
Pregabalin—Anorexia—Carmustine—lymphatic system cancer	0.000508	0.000508	CcSEcCtD
Pregabalin—Infection—Vincristine—lymphatic system cancer	0.000505	0.000505	CcSEcCtD
Pregabalin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000503	0.000503	CcSEcCtD
Pregabalin—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000502	0.000502	CcSEcCtD
Pregabalin—Confusional state—Mitoxantrone—lymphatic system cancer	0.000499	0.000499	CcSEcCtD
Pregabalin—Nervous system disorder—Vincristine—lymphatic system cancer	0.000499	0.000499	CcSEcCtD
Pregabalin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000498	0.000498	CcSEcCtD
Pregabalin—Hypotension—Carmustine—lymphatic system cancer	0.000498	0.000498	CcSEcCtD
Pregabalin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000495	0.000495	CcSEcCtD
Pregabalin—Oedema—Mitoxantrone—lymphatic system cancer	0.000495	0.000495	CcSEcCtD
Pregabalin—Nausea—Fludarabine—lymphatic system cancer	0.000494	0.000494	CcSEcCtD
Pregabalin—Infection—Mitoxantrone—lymphatic system cancer	0.000492	0.000492	CcSEcCtD
Pregabalin—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000492	0.000492	CcSEcCtD
Pregabalin—Shock—Mitoxantrone—lymphatic system cancer	0.000487	0.000487	CcSEcCtD
Pregabalin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000485	0.000485	CcSEcCtD
Pregabalin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000485	0.000485	CcSEcCtD
Pregabalin—Urticaria—Bleomycin—lymphatic system cancer	0.000485	0.000485	CcSEcCtD
Pregabalin—Anorexia—Vincristine—lymphatic system cancer	0.000485	0.000485	CcSEcCtD
Pregabalin—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000483	0.000483	CcSEcCtD
Pregabalin—Body temperature increased—Bleomycin—lymphatic system cancer	0.000482	0.000482	CcSEcCtD
Pregabalin—Insomnia—Carmustine—lymphatic system cancer	0.000482	0.000482	CcSEcCtD
Pregabalin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000481	0.000481	CcSEcCtD
Pregabalin—Irritability—Methotrexate—lymphatic system cancer	0.000479	0.000479	CcSEcCtD
Pregabalin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000479	0.000479	CcSEcCtD
Pregabalin—Paraesthesia—Carmustine—lymphatic system cancer	0.000478	0.000478	CcSEcCtD
Pregabalin—Mood swings—Methotrexate—lymphatic system cancer	0.000476	0.000476	CcSEcCtD
Pregabalin—Hypotension—Vincristine—lymphatic system cancer	0.000475	0.000475	CcSEcCtD
Pregabalin—Dyspnoea—Carmustine—lymphatic system cancer	0.000475	0.000475	CcSEcCtD
Pregabalin—Somnolence—Carmustine—lymphatic system cancer	0.000474	0.000474	CcSEcCtD
Pregabalin—Anorexia—Mitoxantrone—lymphatic system cancer	0.000472	0.000472	CcSEcCtD
Pregabalin—Ataxia—Methotrexate—lymphatic system cancer	0.000472	0.000472	CcSEcCtD
Pregabalin—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000463	0.000463	CcSEcCtD
Pregabalin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000463	0.000463	CcSEcCtD
Pregabalin—Decreased appetite—Carmustine—lymphatic system cancer	0.000463	0.000463	CcSEcCtD
Pregabalin—Hypotension—Mitoxantrone—lymphatic system cancer	0.000463	0.000463	CcSEcCtD
Pregabalin—Insomnia—Vincristine—lymphatic system cancer	0.00046	0.00046	CcSEcCtD
Pregabalin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00046	0.00046	CcSEcCtD
Pregabalin—Paraesthesia—Vincristine—lymphatic system cancer	0.000457	0.000457	CcSEcCtD
Pregabalin—Pain—Carmustine—lymphatic system cancer	0.000455	0.000455	CcSEcCtD
Pregabalin—Constipation—Carmustine—lymphatic system cancer	0.000455	0.000455	CcSEcCtD
Pregabalin—Breast disorder—Methotrexate—lymphatic system cancer	0.000454	0.000454	CcSEcCtD
Pregabalin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000451	0.000451	CcSEcCtD
Pregabalin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00045	0.00045	CcSEcCtD
Pregabalin—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000445	0.000445	CcSEcCtD
Pregabalin—Decreased appetite—Vincristine—lymphatic system cancer	0.000442	0.000442	CcSEcCtD
Pregabalin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000441	0.000441	CcSEcCtD
Pregabalin—Somnolence—Mitoxantrone—lymphatic system cancer	0.00044	0.00044	CcSEcCtD
Pregabalin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000439	0.000439	CcSEcCtD
Pregabalin—Feeling abnormal—Carmustine—lymphatic system cancer	0.000439	0.000439	CcSEcCtD
Pregabalin—Fatigue—Vincristine—lymphatic system cancer	0.000438	0.000438	CcSEcCtD
Pregabalin—Asthenia—Bleomycin—lymphatic system cancer	0.000438	0.000438	CcSEcCtD
Pregabalin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000436	0.000436	CcSEcCtD
Pregabalin—Constipation—Vincristine—lymphatic system cancer	0.000435	0.000435	CcSEcCtD
Pregabalin—Pain—Vincristine—lymphatic system cancer	0.000435	0.000435	CcSEcCtD
Pregabalin—Asthma—Methotrexate—lymphatic system cancer	0.000434	0.000434	CcSEcCtD
Pregabalin—Pruritus—Bleomycin—lymphatic system cancer	0.000432	0.000432	CcSEcCtD
Pregabalin—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00043	0.00043	CcSEcCtD
Pregabalin—Eosinophilia—Methotrexate—lymphatic system cancer	0.00043	0.00043	CcSEcCtD
Pregabalin—Fatigue—Mitoxantrone—lymphatic system cancer	0.000427	0.000427	CcSEcCtD
Pregabalin—Pancreatitis—Methotrexate—lymphatic system cancer	0.000425	0.000425	CcSEcCtD
Pregabalin—Pain—Mitoxantrone—lymphatic system cancer	0.000423	0.000423	CcSEcCtD
Pregabalin—Constipation—Mitoxantrone—lymphatic system cancer	0.000423	0.000423	CcSEcCtD
Pregabalin—Abdominal pain—Carmustine—lymphatic system cancer	0.000421	0.000421	CcSEcCtD
Pregabalin—Body temperature increased—Carmustine—lymphatic system cancer	0.000421	0.000421	CcSEcCtD
Pregabalin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000416	0.000416	CcSEcCtD
Pregabalin—Pancytopenia—Methotrexate—lymphatic system cancer	0.000412	0.000412	CcSEcCtD
Pregabalin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000408	0.000408	CcSEcCtD
Pregabalin—Dysuria—Methotrexate—lymphatic system cancer	0.000406	0.000406	CcSEcCtD
Pregabalin—Neutropenia—Methotrexate—lymphatic system cancer	0.000406	0.000406	CcSEcCtD
Pregabalin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000405	0.000405	CcSEcCtD
Pregabalin—Body temperature increased—Vincristine—lymphatic system cancer	0.000402	0.000402	CcSEcCtD
Pregabalin—Abdominal pain—Vincristine—lymphatic system cancer	0.000402	0.000402	CcSEcCtD
Pregabalin—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.0004	0.0004	CcSEcCtD
Pregabalin—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000396	0.000396	CcSEcCtD
Pregabalin—Urticaria—Mitoxantrone—lymphatic system cancer	0.000393	0.000393	CcSEcCtD
Pregabalin—Hypersensitivity—Carmustine—lymphatic system cancer	0.000392	0.000392	CcSEcCtD
Pregabalin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000391	0.000391	CcSEcCtD
Pregabalin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000391	0.000391	CcSEcCtD
Pregabalin—Pneumonia—Methotrexate—lymphatic system cancer	0.000389	0.000389	CcSEcCtD
Pregabalin—Vomiting—Bleomycin—lymphatic system cancer	0.000388	0.000388	CcSEcCtD
Pregabalin—Infestation NOS—Methotrexate—lymphatic system cancer	0.000387	0.000387	CcSEcCtD
Pregabalin—Infestation—Methotrexate—lymphatic system cancer	0.000387	0.000387	CcSEcCtD
Pregabalin—Depression—Methotrexate—lymphatic system cancer	0.000386	0.000386	CcSEcCtD
Pregabalin—Rash—Bleomycin—lymphatic system cancer	0.000385	0.000385	CcSEcCtD
Pregabalin—Dermatitis—Bleomycin—lymphatic system cancer	0.000384	0.000384	CcSEcCtD
Pregabalin—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000384	0.000384	CcSEcCtD
Pregabalin—Asthenia—Carmustine—lymphatic system cancer	0.000382	0.000382	CcSEcCtD
Pregabalin—Renal failure—Methotrexate—lymphatic system cancer	0.00038	0.00038	CcSEcCtD
Pregabalin—Stomatitis—Methotrexate—lymphatic system cancer	0.000377	0.000377	CcSEcCtD
Pregabalin—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000376	0.000376	CcSEcCtD
Pregabalin—Hypersensitivity—Vincristine—lymphatic system cancer	0.000375	0.000375	CcSEcCtD
Pregabalin—Sweating—Methotrexate—lymphatic system cancer	0.000371	0.000371	CcSEcCtD
Pregabalin—Haematuria—Methotrexate—lymphatic system cancer	0.000369	0.000369	CcSEcCtD
Pregabalin—Epistaxis—Methotrexate—lymphatic system cancer	0.000365	0.000365	CcSEcCtD
Pregabalin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000365	0.000365	CcSEcCtD
Pregabalin—Asthenia—Vincristine—lymphatic system cancer	0.000365	0.000365	CcSEcCtD
Pregabalin—Diarrhoea—Carmustine—lymphatic system cancer	0.000364	0.000364	CcSEcCtD
Pregabalin—Nausea—Bleomycin—lymphatic system cancer	0.000362	0.000362	CcSEcCtD
Pregabalin—Asthenia—Mitoxantrone—lymphatic system cancer	0.000355	0.000355	CcSEcCtD
Pregabalin—Dizziness—Carmustine—lymphatic system cancer	0.000352	0.000352	CcSEcCtD
Pregabalin—Haemoglobin—Methotrexate—lymphatic system cancer	0.000349	0.000349	CcSEcCtD
Pregabalin—Diarrhoea—Vincristine—lymphatic system cancer	0.000348	0.000348	CcSEcCtD
Pregabalin—Hepatitis—Methotrexate—lymphatic system cancer	0.000347	0.000347	CcSEcCtD
Pregabalin—Haemorrhage—Methotrexate—lymphatic system cancer	0.000347	0.000347	CcSEcCtD
Pregabalin—Pharyngitis—Methotrexate—lymphatic system cancer	0.000345	0.000345	CcSEcCtD
Pregabalin—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000343	0.000343	CcSEcCtD
Pregabalin—Urethral disorder—Methotrexate—lymphatic system cancer	0.00034	0.00034	CcSEcCtD
Pregabalin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000339	0.000339	CcSEcCtD
Pregabalin—Vomiting—Carmustine—lymphatic system cancer	0.000339	0.000339	CcSEcCtD
Pregabalin—Dizziness—Vincristine—lymphatic system cancer	0.000336	0.000336	CcSEcCtD
Pregabalin—Rash—Carmustine—lymphatic system cancer	0.000336	0.000336	CcSEcCtD
Pregabalin—Dermatitis—Carmustine—lymphatic system cancer	0.000336	0.000336	CcSEcCtD
Pregabalin—Visual impairment—Methotrexate—lymphatic system cancer	0.000335	0.000335	CcSEcCtD
Pregabalin—Headache—Carmustine—lymphatic system cancer	0.000334	0.000334	CcSEcCtD
Pregabalin—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000328	0.000328	CcSEcCtD
Pregabalin—Eye disorder—Methotrexate—lymphatic system cancer	0.000325	0.000325	CcSEcCtD
Pregabalin—Tinnitus—Methotrexate—lymphatic system cancer	0.000324	0.000324	CcSEcCtD
Pregabalin—Vomiting—Vincristine—lymphatic system cancer	0.000323	0.000323	CcSEcCtD
Pregabalin—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000322	0.000322	CcSEcCtD
Pregabalin—Rash—Vincristine—lymphatic system cancer	0.000321	0.000321	CcSEcCtD
Pregabalin—Dermatitis—Vincristine—lymphatic system cancer	0.00032	0.00032	CcSEcCtD
Pregabalin—Headache—Vincristine—lymphatic system cancer	0.000319	0.000319	CcSEcCtD
Pregabalin—Nausea—Carmustine—lymphatic system cancer	0.000316	0.000316	CcSEcCtD
Pregabalin—Angiopathy—Methotrexate—lymphatic system cancer	0.000315	0.000315	CcSEcCtD
Pregabalin—Vomiting—Mitoxantrone—lymphatic system cancer	0.000315	0.000315	CcSEcCtD
Pregabalin—Immune system disorder—Methotrexate—lymphatic system cancer	0.000314	0.000314	CcSEcCtD
Pregabalin—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000313	0.000313	CcSEcCtD
Pregabalin—Rash—Mitoxantrone—lymphatic system cancer	0.000312	0.000312	CcSEcCtD
Pregabalin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000312	0.000312	CcSEcCtD
Pregabalin—Chills—Methotrexate—lymphatic system cancer	0.000312	0.000312	CcSEcCtD
Pregabalin—Headache—Mitoxantrone—lymphatic system cancer	0.00031	0.00031	CcSEcCtD
Pregabalin—Alopecia—Methotrexate—lymphatic system cancer	0.000307	0.000307	CcSEcCtD
Pregabalin—Mental disorder—Methotrexate—lymphatic system cancer	0.000304	0.000304	CcSEcCtD
Pregabalin—Malnutrition—Methotrexate—lymphatic system cancer	0.000302	0.000302	CcSEcCtD
Pregabalin—Nausea—Vincristine—lymphatic system cancer	0.000302	0.000302	CcSEcCtD
Pregabalin—Dysgeusia—Methotrexate—lymphatic system cancer	0.000296	0.000296	CcSEcCtD
Pregabalin—Nausea—Mitoxantrone—lymphatic system cancer	0.000294	0.000294	CcSEcCtD
Pregabalin—Back pain—Methotrexate—lymphatic system cancer	0.000292	0.000292	CcSEcCtD
Pregabalin—Vision blurred—Methotrexate—lymphatic system cancer	0.000285	0.000285	CcSEcCtD
Pregabalin—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00028	0.00028	CcSEcCtD
Pregabalin—Anaemia—Methotrexate—lymphatic system cancer	0.000279	0.000279	CcSEcCtD
Pregabalin—Malaise—Methotrexate—lymphatic system cancer	0.000273	0.000273	CcSEcCtD
Pregabalin—Vertigo—Methotrexate—lymphatic system cancer	0.000272	0.000272	CcSEcCtD
Pregabalin—Leukopenia—Methotrexate—lymphatic system cancer	0.000271	0.000271	CcSEcCtD
Pregabalin—Cough—Methotrexate—lymphatic system cancer	0.000264	0.000264	CcSEcCtD
Pregabalin—Convulsion—Methotrexate—lymphatic system cancer	0.000262	0.000262	CcSEcCtD
Pregabalin—Myalgia—Methotrexate—lymphatic system cancer	0.000257	0.000257	CcSEcCtD
Pregabalin—Arthralgia—Methotrexate—lymphatic system cancer	0.000257	0.000257	CcSEcCtD
Pregabalin—Chest pain—Methotrexate—lymphatic system cancer	0.000257	0.000257	CcSEcCtD
Pregabalin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000256	0.000256	CcSEcCtD
Pregabalin—Discomfort—Methotrexate—lymphatic system cancer	0.000254	0.000254	CcSEcCtD
Pregabalin—Confusional state—Methotrexate—lymphatic system cancer	0.000249	0.000249	CcSEcCtD
Pregabalin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000247	0.000247	CcSEcCtD
Pregabalin—Infection—Methotrexate—lymphatic system cancer	0.000245	0.000245	CcSEcCtD
Pregabalin—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000242	0.000242	CcSEcCtD
Pregabalin—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000242	0.000242	CcSEcCtD
Pregabalin—Skin disorder—Methotrexate—lymphatic system cancer	0.00024	0.00024	CcSEcCtD
Pregabalin—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000239	0.000239	CcSEcCtD
Pregabalin—Anorexia—Methotrexate—lymphatic system cancer	0.000235	0.000235	CcSEcCtD
Pregabalin—Hypotension—Methotrexate—lymphatic system cancer	0.000231	0.000231	CcSEcCtD
Pregabalin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000225	0.000225	CcSEcCtD
Pregabalin—Insomnia—Methotrexate—lymphatic system cancer	0.000223	0.000223	CcSEcCtD
Pregabalin—Paraesthesia—Methotrexate—lymphatic system cancer	0.000222	0.000222	CcSEcCtD
Pregabalin—Dyspnoea—Methotrexate—lymphatic system cancer	0.00022	0.00022	CcSEcCtD
Pregabalin—Somnolence—Methotrexate—lymphatic system cancer	0.000219	0.000219	CcSEcCtD
Pregabalin—Decreased appetite—Methotrexate—lymphatic system cancer	0.000214	0.000214	CcSEcCtD
Pregabalin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000213	0.000213	CcSEcCtD
Pregabalin—Fatigue—Methotrexate—lymphatic system cancer	0.000213	0.000213	CcSEcCtD
Pregabalin—Pain—Methotrexate—lymphatic system cancer	0.000211	0.000211	CcSEcCtD
Pregabalin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000203	0.000203	CcSEcCtD
Pregabalin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000202	0.000202	CcSEcCtD
Pregabalin—Urticaria—Methotrexate—lymphatic system cancer	0.000196	0.000196	CcSEcCtD
Pregabalin—Abdominal pain—Methotrexate—lymphatic system cancer	0.000195	0.000195	CcSEcCtD
Pregabalin—Body temperature increased—Methotrexate—lymphatic system cancer	0.000195	0.000195	CcSEcCtD
Pregabalin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000182	0.000182	CcSEcCtD
Pregabalin—Asthenia—Methotrexate—lymphatic system cancer	0.000177	0.000177	CcSEcCtD
Pregabalin—Pruritus—Methotrexate—lymphatic system cancer	0.000175	0.000175	CcSEcCtD
Pregabalin—Diarrhoea—Methotrexate—lymphatic system cancer	0.000169	0.000169	CcSEcCtD
Pregabalin—Dizziness—Methotrexate—lymphatic system cancer	0.000163	0.000163	CcSEcCtD
Pregabalin—Vomiting—Methotrexate—lymphatic system cancer	0.000157	0.000157	CcSEcCtD
Pregabalin—Rash—Methotrexate—lymphatic system cancer	0.000156	0.000156	CcSEcCtD
Pregabalin—Dermatitis—Methotrexate—lymphatic system cancer	0.000155	0.000155	CcSEcCtD
Pregabalin—Headache—Methotrexate—lymphatic system cancer	0.000155	0.000155	CcSEcCtD
Pregabalin—Nausea—Methotrexate—lymphatic system cancer	0.000147	0.000147	CcSEcCtD
